Symbols / VVOS $1.36 +4.23%
VVOS Chart
About
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 15.47M |
| Enterprise Value | 21.10M | Income | -17.10M | Sales | 17.32M |
| Book/sh | 0.31 | Cash/sh | 0.34 | Dividend Yield | — |
| Payout | 0.00% | Employees | 262 | IPO | — |
| P/E | — | Forward P/E | -1.08 | PEG | — |
| P/S | 0.89 | P/B | 4.43 | P/C | — |
| EV/EBITDA | -1.38 | EV/Sales | 1.22 | Quick Ratio | 0.70 |
| Current Ratio | 0.78 | Debt/Eq | 493.60 | LT Debt/Eq | — |
| EPS (ttm) | -1.77 | EPS next Y | -1.25 | EPS Growth | — |
| Revenue Growth | 75.70% | Earnings | 2026-03-31 | ROA | -49.76% |
| ROE | -3.35% | ROIC | — | Gross Margin | 55.73% |
| Oper. Margin | -69.79% | Profit Margin | -98.76% | Shs Outstand | 10.47M |
| Shs Float | 7.21M | Short Float | 5.01% | Short Ratio | 5.11 |
| Short Interest | — | 52W High | 7.95 | 52W Low | 1.19 |
| Beta | 7.02 | Avg Volume | 120.63K | Volume | 32.57K |
| Target Price | $5.00 | Recom | None | Prev Close | $1.30 |
| Price | $1.35 | Change | 4.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.33
Latest analyst target
3. DCF / Fair value
$-16.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.33
Low
$2.50
High
$7.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-03 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2025-11-17 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2025-09-09 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-04-15 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2024-11-20 | reit | Ascendiant Capital | Buy → Buy | $7 |
| 2024-11-19 | main | Alliance Global Partners | Buy → Buy | $6 |
| 2024-08-20 | main | Ascendiant Capital | Buy → Buy | $7 |
- Vivos Therapeutics, Inc. Study Affirms Link Between Dental Morphology and Obstructive Sleep Apnea Severity - Quiver Quantitative ue, 17 Mar 2026 12
- Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance Mon, 05 Jan 2026 08
- Ascendiant Capital Maintains Vivos Therapeutics (VVOS) Buy Recommendation - Nasdaq Wed, 03 Dec 2025 08
- Sleep apnea device maker Vivos raises $4.64M in repriced warrant deal - Stock Titan ue, 20 Jan 2026 08
- Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected - simplywall.st Wed, 02 Jul 2025 07
- Vivos Therapeutics Completes Warrant Inducement Financing Transaction - TipRanks ue, 20 Jan 2026 08
- Earnings call transcript: Vivos Therapeutics reports Q2 2025 earnings miss - Investing.com ue, 19 Aug 2025 07
- Sleep apnea device maker Vivos secures $4.64M from warrant exercise - Stock Titan Fri, 16 Jan 2026 08
- Health Catalyst (HCAT) Lags Q4 Earnings Estimates - Yahoo Finance hu, 12 Mar 2026 22
- Vivos Therapeutics, Inc. Plans Q3 2025 Financial Results Release and Investor Conference Call - Quiver Quantitative Wed, 19 Nov 2025 08
- Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth - Investing.com Wed, 19 Nov 2025 08
- Vivos Therapeutics (NASDAQ: VVOS) expands with MISleep-linked Detroit sleep center - Stock Titan ue, 16 Dec 2025 08
- Vivos Therapeutics, Inc. CEO and CFO Set to Discuss Strategic Business Model and Market Opportunities in Upcoming Fireside Chat - Quiver Quantitative Mon, 15 Dec 2025 08
- Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates - Yahoo Finance ue, 03 Mar 2026 08
- Vivos Therapeutics increases at-the-market offering price for common stock - Investing.com Fri, 24 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -10.59M | -20.45M | -25.65M | -18.63M |
| TotalUnusualItems | 3.78M | 1.29M | -911.00K | |
| TotalUnusualItemsExcludingGoodwill | 3.78M | 1.29M | -911.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.14M | -13.58M | -23.84M | -20.29M |
| ReconciledDepreciation | 581.00K | 621.00K | 669.00K | 733.00K |
| ReconciledCostOfRevenue | 6.01M | 5.53M | 6.00M | 4.28M |
| EBITDA | -10.59M | -16.68M | -24.36M | -19.54M |
| EBIT | -11.17M | -17.30M | -25.03M | -20.27M |
| NetInterestIncome | 0.00 | -14.00K | ||
| InterestExpense | 0.00 | 14.00K | ||
| InterestIncome | 117.00K | |||
| NormalizedIncome | -11.14M | -17.36M | -25.13M | -19.38M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.14M | -13.58M | -23.84M | -20.29M |
| TotalExpenses | 26.20M | 31.10M | 41.05M | 36.36M |
| TotalOperatingIncomeAsReported | -11.17M | -17.30M | -25.03M | -20.38M |
| DilutedAverageShares | 5.02M | 1.22M | 920.59K | 849.34K |
| BasicAverageShares | 5.02M | 1.22M | 920.59K | 849.34K |
| DilutedEPS | -2.22 | -11.14 | -25.90 | -24.00 |
| BasicEPS | -2.22 | -11.14 | -25.90 | -24.00 |
| DilutedNIAvailtoComStockholders | -11.14M | -13.58M | -23.84M | -20.29M |
| NetIncomeCommonStockholders | -11.14M | -13.58M | -23.84M | -20.29M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -11.14M | -13.58M | -23.84M | -20.29M |
| NetIncomeIncludingNoncontrollingInterests | -11.14M | -13.58M | -23.84M | -20.29M |
| NetIncomeContinuousOperations | -11.14M | -13.58M | -23.84M | -20.29M |
| TaxProvision | 0.00 | 0.00 | ||
| PretaxIncome | -11.14M | -13.58M | -23.84M | -20.29M |
| OtherIncomeExpense | 35.00K | 3.71M | 1.19M | -803.00K |
| OtherNonOperatingIncomeExpenses | 35.00K | -65.00K | -101.00K | 108.00K |
| SpecialIncomeCharges | 0.00 | 1.29M | -911.00K | |
| OtherSpecialCharges | -1.29M | |||
| WriteOff | 0.00 | 911.00K | ||
| GainOnSaleOfSecurity | 3.78M | |||
| NetNonOperatingInterestIncomeExpense | 0.00 | -14.00K | ||
| InterestExpenseNonOperating | 0.00 | 14.00K | ||
| InterestIncomeNonOperating | 117.00K | |||
| OperatingIncome | -11.17M | -17.30M | -25.03M | -19.47M |
| OperatingExpense | 20.19M | 25.57M | 35.05M | 32.08M |
| DepreciationAmortizationDepletionIncomeStatement | 581.00K | 621.00K | 669.00K | 733.00K |
| DepreciationAndAmortizationInIncomeStatement | 581.00K | 621.00K | 669.00K | 733.00K |
| SellingGeneralAndAdministration | 19.61M | 24.95M | 34.38M | 31.34M |
| SellingAndMarketingExpense | 1.73M | 2.47M | 5.34M | 5.55M |
| GeneralAndAdministrativeExpense | 17.88M | 22.48M | 29.04M | 25.79M |
| OtherGandA | 17.88M | 22.48M | 29.04M | 25.79M |
| GrossProfit | 9.02M | 8.27M | 10.02M | 12.60M |
| CostOfRevenue | 6.01M | 5.53M | 6.00M | 4.28M |
| TotalRevenue | 15.03M | 13.80M | 16.02M | 16.89M |
| OperatingRevenue | 15.03M | 13.80M | 16.02M | 16.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 5.89M | 1.83M | 920.48K | 920.48K |
| ShareIssued | 5.89M | 1.83M | 920.48K | 920.48K |
| TotalDebt | 1.51M | 2.00M | 2.41M | 1.63M |
| TangibleBookValue | 4.74M | -2.85M | 1.66M | 22.36M |
| InvestedCapital | 7.95M | 411.00K | 4.80M | 26.80M |
| WorkingCapital | 2.50M | -4.83M | -1.39M | 19.82M |
| NetTangibleAssets | 4.74M | -2.85M | 1.66M | 22.36M |
| CapitalLeaseObligations | 1.51M | 2.00M | 2.41M | 367.00K |
| CommonStockEquity | 7.95M | 411.00K | 4.80M | 25.54M |
| TotalCapitalization | 7.95M | 411.00K | 4.80M | 25.54M |
| TotalEquityGrossMinorityInterest | 7.95M | 411.00K | 4.80M | 25.54M |
| StockholdersEquity | 7.95M | 411.00K | 4.80M | 25.54M |
| RetainedEarnings | -104.19M | -93.05M | -79.47M | -55.62M |
| AdditionalPaidInCapital | 112.14M | 93.46M | 84.27M | 81.16M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 2.00K |
| CommonStock | 0.00 | 0.00 | 0.00 | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.33M | 10.32M | 8.92M | 8.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.35M | 3.03M | 2.11M | 641.00K |
| EmployeeBenefits | 1.22M | 1.22M | 0.00 | |
| NonCurrentDeferredLiabilities | 97.00K | 289.00K | 112.00K | 343.00K |
| NonCurrentDeferredRevenue | 97.00K | 289.00K | 112.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 1.03M | 1.52M | 1.99M | 298.00K |
| LongTermCapitalLeaseObligation | 1.03M | 1.52M | 1.99M | 298.00K |
| CurrentLiabilities | 4.98M | 7.29M | 6.81M | 7.51M |
| OtherCurrentLiabilities | 273.00K | 198.00K | 145.00K | 466.00K |
| CurrentDeferredLiabilities | 896.00K | 2.14M | 2.93M | 2.40M |
| CurrentDeferredRevenue | 896.00K | 2.14M | 2.93M | 2.40M |
| CurrentDebtAndCapitalLeaseObligation | 477.00K | 474.00K | 419.00K | 1.33M |
| CurrentCapitalLeaseObligation | 477.00K | 474.00K | 419.00K | 69.00K |
| CurrentDebt | 1.26M | |||
| OtherCurrentBorrowings | 1.26M | |||
| PayablesAndAccruedExpenses | 3.33M | 4.48M | 3.32M | 3.77M |
| CurrentAccruedExpenses | 1.75M | 2.01M | 1.91M | 2.85M |
| Payables | 1.58M | 2.47M | 1.41M | 920.00K |
| DuetoRelatedPartiesCurrent | 0.00 | |||
| TotalTaxPayable | 481.00K | 327.00K | ||
| AccountsPayable | 1.10M | 2.15M | 1.41M | 920.00K |
| TotalAssets | 15.28M | 10.73M | 13.72M | 33.69M |
| TotalNonCurrentAssets | 7.81M | 8.27M | 8.30M | 6.37M |
| OtherNonCurrentAssets | 216.00K | 307.00K | 374.00K | |
| NonCurrentPrepaidAssets | 374.00K | 356.00K | ||
| NonCurrentNoteReceivables | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 3.21M | 3.26M | 3.15M | 3.18M |
| OtherIntangibleAssets | 370.00K | 420.00K | 302.00K | 341.00K |
| Goodwill | 2.84M | 2.84M | 2.84M | 2.84M |
| NetPPE | 4.38M | 4.70M | 4.78M | 2.83M |
| AccumulatedDepreciation | -2.86M | -2.33M | -1.75M | -1.24M |
| GrossPPE | 7.24M | 7.03M | 6.53M | 4.07M |
| Leases | 2.48M | 2.48M | 2.48M | 2.39M |
| ConstructionInProgress | 1.86M | 1.44M | 948.00K | 212.00K |
| OtherProperties | 1.55M | 1.79M | 1.84M | 75.00K |
| MachineryFurnitureEquipment | 1.35M | 1.32M | 1.26M | 1.39M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 7.47M | 2.46M | 5.42M | 27.32M |
| OtherCurrentAssets | 783.00K | 616.00K | 1.45M | 1.57M |
| PrepaidAssets | 1.57M | |||
| Receivables | 430.00K | 202.00K | 457.00K | 1.72M |
| OtherReceivables | 516.00K | |||
| NotesReceivable | 0.00 | |||
| AccountsReceivable | 430.00K | 202.00K | 457.00K | 1.20M |
| AllowanceForDoubtfulAccountsReceivable | -390.00K | -268.00K | -712.00K | -180.00K |
| GrossAccountsReceivable | 820.00K | 470.00K | 1.17M | 1.38M |
| CashCashEquivalentsAndShortTermInvestments | 6.26M | 1.64M | 3.52M | 24.03M |
| CashAndCashEquivalents | 6.26M | 1.64M | 3.52M | 24.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.26M | -12.75M | -20.51M | -18.13M |
| RepurchaseOfCapitalStock | 0.00 | -1.50M | ||
| RepaymentOfDebt | 0.00 | -25.00K | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 7.80M | 4.00M | 0.00 | 27.93M |
| CapitalExpenditure | -568.00K | -803.00K | -924.00K | -2.40M |
| InterestPaidSupplementalData | 9.00K | 0.00 | 0.00 | 18.00K |
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 6.26M | 1.64M | 3.52M | 24.03M |
| BeginningCashPosition | 1.64M | 3.52M | 24.03M | 18.21M |
| ChangesInCash | 4.62M | -1.88M | -20.51M | 5.82M |
| FinancingCashFlow | 17.88M | 10.92M | 0.00 | 24.17M |
| CashFlowFromContinuingFinancingActivities | 17.88M | 10.92M | 0.00 | 24.17M |
| NetOtherFinancingCharges | -1.36M | -1.08M | -2.24M | |
| ProceedsFromStockOptionExercised | 11.44M | 8.00M | ||
| NetPreferredStockIssuance | 0.00 | -1.50M | ||
| PreferredStockPayments | 0.00 | -1.50M | ||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 7.80M | 4.00M | 0.00 | 27.93M |
| CommonStockIssuance | 7.80M | 4.00M | 0.00 | 27.93M |
| NetIssuancePaymentsOfDebt | 0.00 | -25.00K | ||
| NetLongTermDebtIssuance | 0.00 | -25.00K | ||
| LongTermDebtPayments | 0.00 | -25.00K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -568.00K | -853.00K | -924.00K | -2.61M |
| CashFlowFromContinuingInvestingActivities | -568.00K | -853.00K | -924.00K | -2.61M |
| NetOtherInvestingChanges | -50.00K | 13.00K | ||
| NetBusinessPurchaseAndSale | 0.00 | -225.00K | ||
| PurchaseOfBusiness | 0.00 | -225.00K | ||
| NetPPEPurchaseAndSale | -568.00K | -803.00K | -924.00K | -2.40M |
| PurchaseOfPPE | -568.00K | -803.00K | -924.00K | -2.40M |
| OperatingCashFlow | -12.69M | -11.95M | -19.59M | -15.73M |
| CashFlowFromContinuingOperatingActivities | -12.69M | -11.95M | -19.59M | -15.73M |
| ChangeInWorkingCapital | -2.94M | 2.86M | 1.71M | 28.00K |
| ChangeInOtherWorkingCapital | -1.43M | -611.00K | 1.15M | -507.00K |
| ChangeInOtherCurrentLiabilities | -129.00K | 1.15M | 151.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -1.09M | 1.16M | -450.00K | 1.26M |
| ChangeInAccruedExpense | -39.00K | 422.00K | -941.00K | 1.12M |
| ChangeInPayable | -1.05M | 734.00K | 491.00K | 139.00K |
| ChangeInAccountPayable | -1.05M | 734.00K | 491.00K | 139.00K |
| ChangeInPrepaidAssets | -62.00K | 912.00K | 110.00K | -949.00K |
| ChangeInReceivables | -228.00K | 255.00K | 746.00K | 228.00K |
| ChangesInAccountReceivables | -228.00K | 255.00K | 746.00K | 228.00K |
| OtherNonCashItems | 11.00K | 87.00K | -9.00K | |
| StockBasedCompensation | 762.00K | 1.11M | 2.40M | 2.66M |
| AssetImpairmentCharge | 0.00 | 911.00K | ||
| DepreciationAmortizationDepletion | 581.00K | 621.00K | 669.00K | 733.00K |
| DepreciationAndAmortization | 581.00K | 621.00K | 669.00K | 733.00K |
| OperatingGainsLosses | 31.00K | -3.04M | -518.00K | 232.00K |
| GainLossOnInvestmentSecurities | 31.00K | -3.04M | 711.00K | 232.00K |
| NetIncomeFromContinuingOperations | -11.14M | -13.58M | -23.84M | -20.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VVOS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|